Combining the experimental vaccine galinpepimut-S (GPS) with the immune checkpoint inhibitor Keytruda (pembrolizumab) induces promising responses ...

Lynparza (olaparib) has been approved in Japan as a maintenance treatment for women with advanced ...

InterVenn Biosciences has raised $34 million to commercialize a new diagnostic tool for ovarian cancer, ...

Rubraca (rucaparib) is superior to chemotherapy at prolonging life without disease worsening in people with advanced ...

IMV‘s immunotherapy DPX-Survivac plus low-dose chemotherapy continues to show sustained benefits in people with heavily treated ...

STRO-002, Sutro Biopharma’s experimental antibody-drug conjugate, continues to be safe and elicit promising responses in ...

A $3.2-million grant from the National Institutes of Health has been awarded to the collaborative ...

Anixa Biosciences has entered in a license agreement with the Cleveland Clinic to obtain the ...

Verastem Oncology has started a Phase 2 clinical trial evaluating its inhibitors, VS-6766 and defactinib, ...

For the first time, researchers safely and effectively treated cells and mice with ovarian cancer ...

Women who use assisted reproductive technology to help them conceive a child appear not to ...

A new $100-million program aims to improve the diversity of participants in U.S. clinical trials with ...

The combination of Keytruda (pembrolizumab) and ALKS 4230 was able to halt disease progression and ...

ImmunoGen has announced a collaboration with Hangzhou Zhongmei Huadong Pharmaceutical Co, a subsidiary of Huadong ...

A blood test measuring levels of the protein cancer antigen 125 (CA125) can help detect ...

The European Commission has approved Lynparza (olaparib), in combination with bevacizumab, as a first-line maintenance ...

The first patient has been dosed in a Phase 2 extension study investigating the cancer ...

The European Commission has approved Zejula (niraparib) as a first-line maintenance therapy for people with ...

TransGene, NEC, and BostonGene have entered a strategic collaboration to test TG4050, an investigational personalized ...

Under its Pilot Study Awards program, the Rivkin Center is funding innovative research projects that ...

The U.S. Food and Drug Administration (FDA) has granted fast track designation to PC14586 as ...

Shattuck Labs has opened a Phase 1 clinical trial to investigate its lead candidate, SL-172154, in ...

The first clinical trial resulting from a new Zenith Epigenetic collaboration with the National Cancer ...

The Ovarian Cancer Research Alliance (OCRA) has partnered with Microsoft‘s AI for Health initiative, with ...

A lab-grown, three-dimensional (3D) ovarian tumor model will give researchers a new way to study ...

When used as a first-line therapy to treat newly diagnosed women with advanced ovarian cancer ...

Fertility-sparing surgery can effectively treat borderline ovarian tumors (BOTs), while preserving a woman’s ability to ...

Updated interim data from a Phase 1 clinical trial continues to support the safety and ...

Lynparza (olaparib), in combination with bevacizumab, has been recommended for approval in the European Union (EU) as a ...

The Committee for Medicinal Products for Human Use (CHMP) has recommended Zejula (niraparib) as a first-line maintenance ...

Compass Therapeutics‘ CTX-2026, an antibody targeting the protein BTN3A1, could be therapeutic in ovarian cancer ...

Newk’s Cares is honoring the legacy of co-founder Lori Newcomb this September during Ovarian Cancer ...

Genetic material collected in routine cervical cancer screenings could be used to screen for ovarian cancer ...

To communicate with platelets and start the process of cancer spread, ovarian cancer cells are ...

The first two patients have been randomized in Phase 2 of the OVATION 2 trial ...

Screening the overall population for mutations in the genes BRCA1 and BRCA2 that can cause breast and ovarian ...

The U.S. Food and Drug Administration (FDA) has given  fast track designation to Mersana Therapeutics’ XMT-1536 as a ...

Elevar Therapeutics and Tanner Pharma Group have partnered to make Apealea (paclitaxel micellar) accessible in ...

Tests used in clinical trials of ovarian cancer to determine if tumors lack the ability ...

Second-line treatment with a combination of bevacizumab plus the chemotherapies carboplatin and pegylated liposomal doxorubicin ...

China’s regulatory agency has granted priority review status to BeiGene‘s new drug application (NDA) requesting ...

China’s regulatory agency has agreed to consider a request that pamiparib, BeiGene‘s investigational PARP inhibitor, be approved ...

A small inhibitor that prevents cells from making ribosomes — the machinery used to produce proteins ...

The addition of Tecentriq (atezolizumab) to first-line treatment with Avastin (bevacizumab) and chemotherapy does not ...

A research collaboration led by the Hudson Institute of Medical Research as been awarded a ...

An ongoing observational registry study is evaluating Kiyatec‘s novel technology, in which a patient’s own ...

The U.S. Food and Drug Administration (FDA) has launched an initiative called Project Patient Voice ...

A team at Griffith University’s Institute for Glycomics in Australia has received $300,000 in funding from The ...

Investigators using targeted proteomics — a technique to detect proteins of interest — on samples of ...

When given alongside Avastin (bevacizumab), mirvetuximab soravtansine leads to promising treatment responses in women with ...

A combination of IMV‘s immunotherapy DPX-Survivac plus intermittent low-dose cyclophosphamide leads to sustained responses in ...

Genetic tests to assess the risk of breast and ovarian cancer can be performed remotely ...

Women who breastfeed are at a significantly lower risk of developing ovarian cancer overall and ...

A new Phase 2 clinical trial in Australia will assess whether exercise can improve the ...

Maintenance therapy with AstraZeneca’s Lynparza (olaparib) extended survival by more than one year in women ...

The U.S. Food and Drug Administration (FDA) has approved Lynparza (olaparib), in combination with bevacizumab, as a first-line maintenance ...

STRO-002, an investigational antibody-drug conjugate, continues to show promising safety and anti-tumor activity in women ...

The U.S. Food and Drug Administration (FDA) has approved Zejula (niraparib) as a first-line maintenance therapy for women ...

Women living in rural areas in the U.S. are significantly more likely to have metastatic ...

A Phase 1b/2 trial investigating Vigeo Therapeutics‘ VT1021 as a stand-alone treatment for advanced ovarian cancer ...

Treatment with XMT-1536 appears to be safe, with promising responses shown in heavily pretreated patients ...

Senti Biosciences is working with RoosterBio to ensure a quality supply of its candidate gene-modified cell therapies ...

Treatment with Acelarin led to one complete response and two partial responses in heavily pre-treated women with ...

The immunotherapy candidate GEN-1 has shown encouraging results in patients newly diagnosed with advanced ovarian ...

Disrupting genes essential for the cellular recycling process known as autophagy increases the frequency of ...

The Chinese regulatory agency has agreed to review Zai Lab‘s application asking that Zejula (niraparib) ...